Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amplitude Inc (AMPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amplitude Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while Amplitude Inc trades at $9.39 (market cap $1.22B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 32.7× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMPL | |
|---|---|---|
Market Cap | $39.89B | $1.22B |
Sector | Health | Technology |
52-Week High | $491.22 | $13.04 |
52-Week Low | $278.09 | $5.61 |
Enterprise Value | $38.15B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →
